Skip to main content
Scope Fluidics S.A. logo

Scope Fluidics S.A. — Investor Relations & Filings

Ticker · SCP ISIN · PLSCPFL00018 LEI · 259400EUNFX4E2BEHU15 WAR Professional, scientific and technical activities
Open in API
Filings indexed 510 across all filing types
Latest filing 2026-05-06 Regulatory Filings
Country PL Poland
Listing WAR SCP

About Scope Fluidics S.A.

https://scopefluidics.com/

Scope Fluidics S.A. is a biotechnology company that develops innovative medical diagnostic solutions based on microfluidic technologies. The company's business model involves incubating projects within special-purpose vehicles (SPVs) with the goal of selling them to global strategic partners. Its primary project, developed by its subsidiary Bacteromic Sp. z o.o., is the BACTEROMIC system. This automated system provides rapid, comprehensive antimicrobial susceptibility testing (AST) to address the challenge of antibiotic resistance. Previously, the company developed the PCR|ONE system for rapid molecular diagnostics through its Curiosity Diagnostics SPV, which was acquired by Bio-Rad in 2022. The company focuses on creating fast, effective, and accessible diagnostic tools to improve healthcare outcomes.

Recent filings

Filing Released Lang Actions
zal01_SCP_rbESPI_202615_wykaz_5proc_zalacznik.pdf
Regulatory Filings
2026-05-06 Polish
Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na Zwyczajnym Walnym Zgromadzeniu, które odbyło się w 6 maja 2026 r. - Content (PL)
Regulatory Filings
2026-05-06 Polish
Treść uchwał podjętych przez ZWZ Scope Fluidics S.A. 06052026
Regulatory Filings
2026-05-06 Polish
Treść uchwał podjętych przez ZWZ Scope Fluidics w dniu 6 maja 2026 r. - Content (PL)
Regulatory Filings
2026-05-06 Polish
Rozpoczęcie w USA współpracy dotyczącej przeprowadzenia badań klinicznych na potrzeby procesu rejestracji FDA systemu BACTEROMIC z panelem UNI FAST - Content (PL)
Regulatory Filings Classification · 65% confidence The document is a brief operational update (in Polish) referencing a previous current report (nr 8/2026) and announcing the start of clinical trials for FDA registration of the BACTEROMIC system. It does not contain financial results, dividend announcements, management changes, or solicit requests, nor is it a detailed investor presentation or formal regulatory form like a 10-K. It fits the fallback category for general regulatory announcements and miscellaneous filings: Regulatory Filings (RNS).
2026-04-21 Polish
Sprawozdanie RN za 2025 rok
Governance Information Classification · 93% confidence The document is the Supervisory Board’s Report (“Sprawozdanie Rady Nadzorczej”) covering the Board’s evaluation of the standalone and consolidated financial statements, the Management Board’s proposals, the Board’s activity, internal controls, governance, committee composition, and independence. This is clearly a corporate governance report detailing board structure, governance practices, and oversight activities rather than an annual report, earnings release, or management discussion. Therefore, it fits the Governance Information (CGR) category.
2026-04-09 Polish

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.